How to Choose a CDMO for High-Potency APIs (HPAPI)

The short answer: Choosing a CDMO for a high-potency API (HPAPI) is a containment and cross-contamination decision first and a chemistry decision second. Confirm the site has a documented occupational exposure banding process and has handled compounds in your band before; that its containment design (isolators, closed transfers, split-butterfly valves, dedicated air handling) is backed by surrogate monitoring data, not brochure claims; that, if the facility is shared, it sets health-based exposure limits and cleaning limits the way EU GMP Chapters 3 and 5 and the EMA's 2014 guideline require; that it has trace-level analytical capability to prove cleaning; and that its inspection record is clean. Then look at scale, lead time and price.

What counts as high potency

There is no single regulatory definition. Industry practice bands compounds by their occupational exposure limit (OEL): an 8-hour time-weighted average airborne concentration below which workers are not expected to suffer adverse effects. Compounds with an OEL of roughly 10 µg/m³ or lower are commonly treated as highly potent, and the most potent (sub-microgram, sometimes nanogram, limits) include cytotoxic oncology agents, antibody-drug-conjugate payloads, some hormones and prostaglandins, and a growing number of peptides and small molecules designed for low doses. Banding schemes differ between CDMOs (four, five or six bands are all in use), so ask for the OEL the site assigned to your compound, who assigned it, and the toxicology data they used, rather than comparing band labels across companies.

Why the facility matters more than the chemist

Most CDMOs can run a synthesis or a blend. Few can do it when a few micrograms escaping a process represent a worker-safety incident and a cross-contamination risk for every other product in the building. The failure modes are specific: an open charging step that defeats an otherwise closed train, a shared dust-collection system, a cleaning method that cannot detect the residue at the limit the toxicology demands, or a technician trained on a different compound's procedures. None of these shows up in a capability statement. They show up in design documents, monitoring data and the site's own deviations.

The checklist

1. Banding and toxicology

• A written procedure for assigning an OEL or occupational exposure band, with toxicologist involvement, and the record for compounds in your class.
• Experience with compounds in your band or more potent, by number of campaigns and years, with references you can call.
• A permitted daily exposure (PDE) or health-based exposure limit (HBEL) derivation for your compound, because that figure drives cleaning limits and shared-facility decisions.

2. Containment design and proof

• Primary containment appropriate to the band: isolators or glove boxes for the most potent compounds, closed transfers, split-butterfly or alpha-beta valves, contained sampling and dispensing.
• Secondary containment: airflow cascades, dedicated or segregated air handling with HEPA on exhaust, airlocks, pressure regimes documented and monitored.
• Surrogate monitoring data (lactose, naproxen sodium or similar placebo compounds measured during representative operations) showing the achieved containment performance against the target for your band. Ask for the report, not the summary.
• Waste and effluent handling for potent residues, including deactivation where relevant.

3. Dedicated versus shared facilities

Dedicated suites remove the cross-contamination question but cost more and book out. Shared multi-product facilities are acceptable for many potent compounds if the site follows the risk-based approach EU GMP Chapters 3 and 5 adopted in 2015, using health-based exposure limits per the EMA's guideline on setting HBELs for shared facilities (EMA/CHMP/CVMP/SWP/169430/2012) to justify sharing and to set cleaning limits. Ask how the site decides what may share a suite with your product, how campaign changeovers are controlled, and what its most recent cross-contamination risk assessment concluded. Compounds with certain properties (highly sensitising materials, some cytotoxics) still warrant dedicated equipment or facilities in practice.

4. Cleaning validation and analytical capability

• Cleaning limits derived from the HBEL/PDE, not from the older default fractions of a therapeutic dose.
• Validated cleaning methods with analytical sensitivity at the limit: for sub-microgram limits this usually means LC-MS or equivalent, with swab and rinse recovery studies.
• Visual inspection criteria and the evidence that residues are visible at or below the limit, or an acknowledgement that they are not.
• Campaign and changeover records showing the cleaning programme works in practice.

5. People, procedures and surveillance

Training specific to potent handling, medical surveillance programmes, documented personal protective equipment regimes as a last line not a first, and a culture visible in the deviation log: a site with zero potent-handling deviations over years is either exceptional or not recording them.

6. Scale, form and the hand-offs

HPAPI campaigns are often small in mass and large in effort. Confirm the site's equipment train covers your batch size without open steps, that it can take the compound through the dosage form you need (potent oral solids and sterile products have their own containment questions, covered in the oral solid dose and sterile fill-finish guides), and that the hand-off between API and drug product does not pass through an uncontained logistics step. For antibody-drug conjugates, the payload-linker, conjugation and fill-finish stages each carry a containment question of their own.

7. Regulatory record and logistics

Check Form 483, Warning Letter and recall history with particular attention to cross-contamination, cleaning validation and data-integrity observations; these are the categories that matter most for potent products. Confirm the site holds the licences your compound needs (controlled-substance licences for some opioids and cytotoxics), and that it can ship the material under the correct dangerous-goods classification with a cold chain if required.

Questions that separate real capability from claimed capability

1. "What OEL did you assign to our compound, who assigned it and from what data?"
2. "Show us the surrogate monitoring report for the operations our process will use."
3. "What is the most potent compound you have run in the suite you propose, and what was its PDE?"
4. "How did you set the cleaning limit for the last changeover in that suite, and what method verified it?"
5. "Which products share the suite and the air handling, and when was the cross-contamination risk assessment last reviewed?"
6. "What potent-handling deviations have you had in the last two years and what changed?"

A site that answers all six with documents is a candidate. A site that answers with adjectives is not.

Where to find candidates

PharmaTek's directory screens manufacturers against live FDA enforcement data and flags facilities with high-potency capability where the site has recorded it; the API directory shows which suppliers hold an active DMF or CEP for a given substance. For a vendor-neutral shortlist with the compliance screen done, the Sourcing Desk returns compared options for a fixed fee. Once a site is chosen, the technology transfer checklist covers the hand-over, and an independent tech-transfer readiness review can check the plan before documents change hands.

Frequently asked questions

What is a high-potency API? An active pharmaceutical ingredient that is pharmacologically active at very low doses and therefore needs strict containment to protect workers and other products. Industry practice classes compounds by occupational exposure limit; those at roughly 10 µg/m³ or below over an 8-hour shift are commonly treated as highly potent, with cytotoxics, ADC payloads, some hormones and low-dose peptides at the most potent end.

What containment should an HPAPI CDMO have? Primary containment matched to the band (isolators or glove boxes for the most potent compounds, closed transfers, split-butterfly valves, contained sampling), secondary containment through pressure cascades and dedicated or segregated air handling with HEPA exhaust, waste deactivation, and, critically, surrogate monitoring data proving the achieved performance against the target for the band.

Can a high-potency API be made in a shared facility? Often yes, under the risk-based approach in EU GMP Chapters 3 and 5 using health-based exposure limits to justify sharing and to set cleaning limits, with validated cleaning methods sensitive enough to prove them. Some materials, such as highly sensitising compounds and certain cytotoxics, still warrant dedicated equipment or facilities in practice. Ask the site how it decides.

How are cleaning limits set for potent compounds? From a health-based exposure limit or permitted daily exposure derived by a toxicologist from the compound's pharmacology and toxicology data, carried through to a maximum allowable carryover for the next product. The analytical method verifying cleaning must detect residue at that limit, which for sub-microgram compounds usually means LC-MS with demonstrated swab and rinse recovery.

What inspection findings matter most for HPAPI sites? Cross-contamination controls, cleaning validation adequacy, containment and facility design observations, and data integrity in the analytical records that prove cleaning. These appear in FDA Form 483s and Warning Letters and in EU inspection outcomes; PharmaTek links them to company profiles so they can be screened before engagement.

---

Looking for a potent-handling site? Screen candidates against their FDA record in the directory, or send the brief to the Sourcing Desk.